MRI简化风险评分预测uHCC三联治疗客观缓解
本研究回顾性纳入223例接受HAIC联合靶向及免疫治疗的不切肝细胞癌患者,基于治疗前Gd-EOB-DTPA MRI建立影像风险评分并构建列线图。MRI三项征象为独立预测因素,列线图训练集AUC为0.890,外部验证集AUC为0.841,模型显著优于BCLC、ALBI、Child-Pugh及Six-and-Twelve分期系统。
要点
- 不规则形态、环形强化、瘤周低信号为初始ORR的独立负性预测因素
- I-score≥2提示高危,初始ORR概率较低且PFS与OS较差
- 列线图可非侵入性预测初始客观缓解并优于传统分期系统
核心结论
- 基于Gd-EOB-DTPA MRI的简化风险评分及列线图可无创预测uHCC三联治疗的初始客观缓解并分层预后
研究设计与样本
- 回顾性多中心研究,纳入223例uHCC患者
- 训练集127例,外部测试集96例,来自两个医疗中心
- 治疗前均行Gd-EOB-DTPA增强MRI检查
- 采用多因素逻辑回归确定独立预测因素,LASSO回归筛选列线图变量
- 模型性能经AUC、校准曲线、混淆矩阵、决策曲线分析评估,并做内部bootstrap与外部验证
关键影像表现/征象
- 不规则形态、环形强化、瘤周低信号为治疗前MRI上可见的三项负性预测征象
- I-score公式为:1×不规则形态+1×环形强化+2×瘤周低信号,最佳截断值为1.5
诊断标准与关键数值
- 不规则形态、环形强化、瘤周低信号为初始ORR的独立负性预测因素
- I-score公式:1×不规则形态+1×环形强化+2×瘤周低信号,最佳截断值为1.5
- 列线图纳入BMI>22.55、PA<182.5 mg/L、NLR>2.37及I-score≥2
- 列线图ORR预测AUC:训练集0.890,外部验证集0.841
- 校准P>0.05,SHAP分析显示I-score为最重要的贡献变量
临床应用与阅片要点
- 阅片时应主动评估肿瘤形态是否规则、有无环形强化及瘤周低信号
- 三项征象均存在时I-score≥2,应提示临床初始ORR概率较低
- 该模型优于BCLC、ALBI、Child-Pugh及Six-and-Twelve分期系统,可用于治疗决策参考
局限性
- 回顾性研究设计
- 样本量223例,来自两个医疗中心
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study aimed to develop and validate a simplified risk score based on pretreatment Gd‑EOB‑DTPA MRI features for the noninvasive prediction of initial objective response rate (ORR) in patients with unresectable hepatocellular carcinoma (uHCC) undergoing triple therapy (hepatic arterial infusion chemotherapy [HAIC], tyrosine kinase inhibitors, and immune checkpoint inhibitors).
METHODS: This retrospective study enrolled 223 uHCC patients from two medical centers who underwent Gd‑EOB‑DTPA‑enhanced MRI prior to initiating triple therapy (training set: n = 127; external test set: n = 96). Imaging features were evaluated and extracted. Independent predictors of initial ORR were identified by multivariate logistic regression to build a simplified imaging risk score (I-score), and a nomogram was constructed to visualize the final predictive model. Model performance was assessed by AUC, calibration (Hosmer‑Lemeshow test), confusion matrix, and decision curve analysis (DCA), with internal bootstrap and external validation. SHAP analysis provided interpretability. Patients were stratified into low‑ and high‑risk groups, and Kaplan‑Meier curves for progression‑free survival (PFS) and overall survival (OS) were compared.
RESULTS: Three MRI features (irregular morphology, rim enhancement, peritumoral low signal) were independent negative predictors of initial ORR. The simplified I-score was formulated as: 1×(irregular morphology) + 1 × (rim enhancement) + 2 × (peritumoral low signal), with an optimal cut-off of 1.5. Following LASSO regression, BMI > 22.55, PA < 182.5 mg/L, NLR > 2.37, and I-score ≥ 2 were included in the nomogram. The nomogram achieved AUCs of 0.890 in training and 0.841 in validation for ORR prediction, demonstrating good calibration (P > 0.05) and clinical benefit. SHAP analysis identified I-score as the most important contributor. The model significantly outperformed BCLC, ALBI, Child‑Pugh, and Six‑and‑Twelve staging systems (all P < 0.05). High‑risk patients had significantly worse PFS and OS than low‑risk patients.
CONCLUSION: The MRI‑based simplified risk score and the derived nomogram offer a noninvasive and precise method for predicting initial ORR and classifying prognosis in uHCC patients undergoing triple therapy.
引用
- Wang, Feng, Liu, et al. A simplified MRI‑based risk score and nomogram to predict initial objective response in unresectable hepatocellular carcinoma treated with HAIC, targeted therapy, and immunotherapy: a multicenter study. Abdom Radiol (NY). 2026. PMID: 42579007. doi:10.1007/s00261-026-05732-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。